AstraZeneca is one of the two pharmaceutical companies initially involved with the set-up of the National Lung Matrix Trial, committing five of its investigational targeted therapies in addition to an immunotherapy treatment, used within the first non-actionable cohort of patients. Further agents from the AstraZeneca pipeline may be added throughout the course of the trial.
Pfizer Ltd is one of the two pharmaceutical companies initially involved with the set-up of the National Lung Matrix Trial, committing two of its investigational targeted therapies to the trial.
Mirati Therapeutics were previously a pharmaceutical partner of the National Lung Matrix Trial, committing one investigational targeted therapy, Sitravatinib, before this arm closed in June 2019.
Fisher Clinical Services is the drug distribution vendor for the National Lung Matrix Trial, also overseeing QP release, packaging and distribution of AstraZeneca drugs.
Cenduit provide an Interactive Response Technology system, used by sites for the AstraZeneca drugs, allowing control of drug receipt and dispensing, as well as automatically re-ordering stock as required.
De Santo/Mussai/Middleton Laboratory The laboratory team are based within the Institute of Immunology and Immunotherapy at the University of Birmingham and manage the receipt and processing of all peripheral blood mononuclear cell (PBMC) samples collected from Arm NA patients.
Human Biomaterials Resource Centre (HBRC) The HBRC is a Human Tissue Authority licensed human sample biorepository centre based within the University of Birmingham. They manage the receipt and interim storage of all optional research biopsies, repeat biopsies for PDL1 testing from Arm NA patients, and whole blood germline DNA and ctDNA samples.
Experimental Cancer Medicine Centres The success of the National Lung Matrix trial is reliant on the expertise and enthusiasm of the research teams based within each ECMC centre currently recruiting patients.